Randomized phase III trial comparing bexarotene (L1069-49)/cisplatin/ vinorelbine with cisplatin/vinorelbine in chemotherapy-naïve patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I

Journal of Clinical Oncology

Volumn 26, Issue 11, 2008, Pages 1886-1892

  Ramlau, Rodryg ^a   Zatloukal, Petr ^b   Jassem, Jacek ^b   Schwarzenberger, Paul ^b   Orlov, Sergei V ^b   Gottfried, Maya ^b   Pereira, Jose Rodrigues ^b   Temperley, Guillermo ^b   Negro Vilar, Rosa ^b   Rahal, Samia ^b   Zhang, Joseph K ^b   Negro Vilar, Andres ^b   Dziewanowska, Zofia E ^b  

^a Oncology Department   (Poland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; BEXAROTENE; CARBOPLATIN; CIPROFIBRATE; CISPLATIN; FENOFIBRATE; GEMCITABINE; NAVELBINE; PACLITAXEL; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; TETRALIN DERIVATIVE; TRIACYLGLYCEROL; TUMOR MARKER; VINBLASTINE;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL EVALUATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DYSPNEA; FEBRILE NEUTROPENIA; FEMALE; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; HYPOTHYROIDISM; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DISEASE COURSE; LUNG TUMOR; METASTASIS; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; SURVIVAL; SURVIVAL RATE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DISEASE PROGRESSION; FEMALE; HUMANS; HYPERTRIGLYCERIDEMIA; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; SURVIVAL ANALYSIS; SURVIVAL RATE; TETRAHYDRONAPHTHALENES; TRIGLYCERIDES; TUMOR MARKERS, BIOLOGICAL; VINBLASTINE;

EID: 42949162662     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.12.2614     Document Type: Article

References (27)

1. Parkin DM, Bray FI, Devesa SS: Cancer burden in the year 2000: The global picture. Eur J Cancer 37:S4-S66, 2001 (suppl)
2. Le Chevalier T, Brisgand D, Douillard JY, et al: Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: Results of a European multicenter trial including 612 patients. J Clin Oncol 12:360-367, 1994
3. Wozniak AJ, Crowley JJ, Blacerzak SP, et al: Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: A Southwest Oncology Group study. J Clin Oncol 16:2459-2465, 1998
4. Comella P, Frasci G, Panza N, et al: Randomized trial comparing cisplatin, gemcitabine, and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small-cell lung cancer: Interim analysis of a phase III trial of the Southern Italy Cooperative Oncology Group. J Clin Oncol 18:1451-1457, 2000
5. Kelly K, Crowley J, Bunn PA Jr, et al: Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small cell lung cancer: A Southwest Oncology Group trial. J Clin Oncol 19:3210-3218, 2001
6. Fossella F, Pereira JR, Von Pawel J, et al: Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small cell lung cancer: The TAX 326 Study Group. J Clin Oncol 21:3016-3024, 2003
7. Scagliotti GV, De Marinis F, Rinaldi M, et al: Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 20:4285-4291, 2002
8. Sandler AB, Gray R, Brahmer J, et al: Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial - E4599. J Clin Oncol 23:2s, 2005 (suppl; abstr 4)
9. Boehm MF, Mc Clurg MR, Pathirata C, et al: Synthesis of high specific activity [3H]-9-cis-retinoic acid and its application for identifying retinoids with unusual binding properties. J Med Chem 37:408-414, 1994
10. Picard E, Seguin C, Monhoven N, et al: Expression of retinoid receptor genes and proteins in non-small-cell lung cancer. J Natl Cancer Inst 91:1059-1066, 1999
11. Brabender J, Danenberg KD, Metzger R, et al: The role of retinoid X receptor messenger RNA expression in curatively resected non-small cell lung cancer. Clin Cancer Res 8:438-443, 2002
12. Brabender J, Metzger R, Salonga D, et al: Comprehensive expression analysis of retinoic acid receptors and retinoid X receptors in non-small cell lung cancer: Implications for tumor development and prognosis. Carcinogenesis 26:525-530, 2005
13. Miller VA, Benedetti FM, Rigas JR, et al: Initial clinical trial of a selective retinoid X receptor ligand, LGD1069. J Clin Oncol 15:790-795, 1997
14. Rizvi NA, Marshall JL, Dahut W, et al: A phase I study of LGD1069 in adults with advanced cancer. Clin Cancer Res 5:1658-1664, 1999
15. Khuri FR, Rigas JR, Figlin RA, et al: Multi-institutional phase I/II trial of oral bexarotene in combination with cisplatin and vinorelbine in previously untreated patients with advanced non-small-cell lung cancer. J Clin Oncol 19:2626-2637, 2001
16. Rottman JN, Widom RL, Nadal-Ginard B, et al: A retinoic acid-responsive element in the apolipoprotein AI gene distinguishes between two different retinoic acid response pathways. Mol Cell Biol 11:3814-3820, 1991
17. Rigas JR, Dragnev KH: Emerging role of rexinoids in non-small cell lung cancer: Focus on bexarotene. Oncologist 10:22-33, 2005
18. Blumenschein GR Jr, Khuri FR, von Pawel J, et al: Phase III trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy-naïve patients with advanced or metastatic non-small-cell lung cancer: SPIRIT II. J Clin Oncol 26:1879-1885, 2008
19. Rizvi N, Hawkins MJ, Eisenberg PD, et al: Placebo-controlled trial of bexarotene, a retinoid X receptor agonist, as maintenance therapy for patients treated with chemotherapy for advanced non-small-cell lung cancer. Clin Lung Cancer 2:210-215, 2001
20. Govindan R, Crowley J, Schwartzberg L, et al: Phase II trial of bexarotene capsules in patients with advanced non-small cell lung cancer (NSCLC) after failure of tw or more previous therapies. J Clin Oncol 24:4848-4854, 2006
21. Rigas JR, Dragnev KH, Petty WJ, et al: A proof-of-principle trial of bexarotene in patients (pts) with resectable non-small cell lung cancer (NSCLC). J Clin Oncol 23:654s, 2005 (suppl; abstr 7136)
22. Petty WJ, Dragnev KH, Memoli VA, et al: Proof-of-principle clinical trial of bexarotene for the treatment of non-small cell lung cancer. Chest 128:312S, 2005
23. Negro-Vilar A, Gatzemeier U, Ramlau R, et al: Biomarker correlates of survival in NSCLC: Role of RXRβ and PPARγ in mediating bexarotene impact on patient survival. J Clin Oncol 24:420s, 2006 (suppl; abstr 7227)
24. Dziewanowska Z, Zhang J, Sun S, et al: Components of metabolic syndrome correlate with longer survival in NSCLC in bexarotene-treated patients with high hypertriglyceridemia in SPIRIT I and II trials: A retrospective analysis. J Clin Oncol 24:398s, 2006 (suppl; abstr 7137)
25. Khurana V, Bejjanki HR, Caldito G, et al: Statins reduce the risk of lung cancer in humans: A large case-control study of US veterans. Chest 131:1282-1288, 2007
26. Rizvi N, Miller WH Jr, Aisner J, et al: Retinoid-X-receptor agonist, bexarotene (Targretin capsules), in a phase I-II trial with carboplatin and paclitaxel in patients with chemotherapy-naive advanced non-small-cell lung cancer (NSCLC). Presented at the American Society of Clinical Oncology Molecular Therapeutics Symposium, November 8-10, 2006, San Diego, California
27. Edelman MJ, Smith R, Hausner P, et al: Phase II trial of the novel retinoid, bexarotene, and gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 23:5774-5778, 2005